Sandbox ID Cardiovascular: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
mNo edit summary
mNo edit summary
Line 1: Line 1:
* Endocarditis<ref>{{Cite journal| doi = 10.1161/CIRCULATIONAHA.105.165564| issn = 1524-4539| volume = 111| issue = 23| pages = –394-434| last1 = Baddour| first1 = Larry M.| last2 = Wilson| first2 = Walter R.| last3 = Bayer| first3 = Arnold S.| last4 = Fowler| first4 = Vance G.| last5 = Bolger| first5 = Ann F.| last6 = Levison| first6 = Matthew E.| last7 = Ferrieri| first7 = Patricia| last8 = Gerber| first8 = Michael A.| last9 = Tani| first9 = Lloyd Y.| last10 = Gewitz| first10 = Michael H.| last11 = Tong| first11 = David C.| last12 = Steckelberg| first12 = James M.| last13 = Baltimore| first13 = Robert S.| last14 = Shulman| first14 = Stanford T.| last15 = Burns| first15 = Jane C.| last16 = Falace| first16 = Donald A.| last17 = Newburger| first17 = Jane W.| last18 = Pallasch| first18 = Thomas J.| last19 = Takahashi| first19 = Masato| last20 = Taubert| first20 = Kathryn A.| last21 = Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease| last22 = Council on Cardiovascular Disease in the Young| last23 = Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia| last24 = American Heart Association| last25 = Infectious Diseases Society of America| title = Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America| journal = Circulation| date = 2005-06-14| pmid = 15956145}}</ref>
* Endocarditis<ref>{{Cite journal| doi = 10.1161/CIRCULATIONAHA.105.165564| issn = 1524-4539| volume = 111| issue = 23| pages = –394-434| last1 = Baddour| first1 = Larry M.| last2 = Wilson| first2 = Walter R.| last3 = Bayer| first3 = Arnold S.| last4 = Fowler| first4 = Vance G.| last5 = Bolger| first5 = Ann F.| last6 = Levison| first6 = Matthew E.| last7 = Ferrieri| first7 = Patricia| last8 = Gerber| first8 = Michael A.| last9 = Tani| first9 = Lloyd Y.| last10 = Gewitz| first10 = Michael H.| last11 = Tong| first11 = David C.| last12 = Steckelberg| first12 = James M.| last13 = Baltimore| first13 = Robert S.| last14 = Shulman| first14 = Stanford T.| last15 = Burns| first15 = Jane C.| last16 = Falace| first16 = Donald A.| last17 = Newburger| first17 = Jane W.| last18 = Pallasch| first18 = Thomas J.| last19 = Takahashi| first19 = Masato| last20 = Taubert| first20 = Kathryn A.| last21 = Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease| last22 = Council on Cardiovascular Disease in the Young| last23 = Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia| last24 = American Heart Association| last25 = Infectious Diseases Society of America| title = Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America| journal = Circulation| date = 2005-06-14| pmid = 15956145}}</ref>
:* Culture-negative endocarditis:
:* Culture-negative endocarditis:
::* {{Regimen|Native_valve_endocarditis|– Preferred regimen: 123 <br> – Alternative regimen: 123}}
::* {{Regimen|Native_valve_endocarditis| – Preferred regimen: 123 <br> – Alternative regimen: 123}}
::* {{Regimen|Prosthetic_valve_endocarditis|– Preferred regimen: 123 <br> – Alternative regimen: 123}}
::* {{Regimen|Prosthetic_valve_endocarditis| – Preferred regimen: 123 <br> – Alternative regimen: 123}}


:* Culture-directed antimicrobial therapy:
:* Culture-directed antimicrobial therapy:
::* {{Regimen|Highly_Penicillin-Susceptible_Viridans_Group_Streptococci_and_Streptococcus_bovis|* Preferred regimen: Penicillin G 12–18 million U/24 h IV either continuously or in 4 or 6 equally divided doses for 4 weeks {{or}} Ceftriaxone 2g/24h IV/IM in 1 dose for 4 weeks (pediatric dose: penicillin 200,000 U/kg per 24 h IV in 4–6 equally divided doses; ceftriaxone 100 mg/kg per 24 h IV/IM in 1 dose) <br> – Alternative regimen (1): Penicillin G 12–18 million U/24 h IV either continuously or in 6 equally divided doses for 2 weeks {{or}} Ceftriaxone 2g/24h IV/IM in 1 dose for 2 weeks {{and}} Gentamicin 3mg/kg per 24h IV/IM in 1 dose for 2 weeks (pediatric dose: penicillin 200 000 U/kg per 24 h IV in 4–6 equally divided doses; ceftriaxone 100 mg/kg per 24 h IV/IM in 1 dose; gentamicin 3 mg/kg per 24 h IV/IM in 1 dose or 3 equally divided doses) <br> – Alternative regimen (2): Vancomycin 30 mg/kg per 24 h IV in 2 equally divided doses not to exceed 2 g/24 h for 4 weeks (pediatric dose: 40 mg/kg per 24 h IV in 2–3 equally divided doses)}}
::* {{Regimen|Highly_Penicillin-Susceptible_Viridans_Group_Streptococci_and_Streptococcus_bovis| – Preferred regimen: Penicillin G 12–18 million U/24 h IV either continuously or in 4 or 6 equally divided doses for 4 weeks {{or}} Ceftriaxone 2g/24h IV/IM in 1 dose for 4 weeks (pediatric dose: penicillin 200,000 U/kg per 24 h IV in 4–6 equally divided doses; ceftriaxone 100 mg/kg per 24 h IV/IM in 1 dose) <br> – Alternative regimen (1): Penicillin G 12–18 million U/24 h IV either continuously or in 6 equally divided doses for 2 weeks {{or}} Ceftriaxone 2g/24h IV/IM in 1 dose for 2 weeks {{and}} Gentamicin 3mg/kg per 24h IV/IM in 1 dose for 2 weeks (pediatric dose: penicillin 200 000 U/kg per 24 h IV in 4–6 equally divided doses; ceftriaxone 100 mg/kg per 24 h IV/IM in 1 dose; gentamicin 3 mg/kg per 24 h IV/IM in 1 dose or 3 equally divided doses) <br> – Alternative regimen (2): Vancomycin 30 mg/kg per 24 h IV in 2 equally divided doses not to exceed 2 g/24 h for 4 weeks (pediatric dose: 40 mg/kg per 24 h IV in 2–3 equally divided doses)}}




Line 11: Line 11:




::* {{Regimen|Bartonella|– Preferred regimen: 123 <br> – Alternative regimen: 123}}
::* {{Regimen|Bartonella| – Preferred regimen: 123 <br> – Alternative regimen: 123}}
::* Chlamydia
::* Chlamydia
::* Coagulase-negative Staphylococcus
::* Coagulase-negative Staphylococcus
::* {{Regimen|Coxiella_burnetii|– Preferred regimen: 123 <br> – Alternative regimen: 123}}
::* {{Regimen|Coxiella_burnetii| – Preferred regimen: 123 <br> – Alternative regimen: 123}}
::* {{Regimen|Enterococcus|– Preferred regimen: 123 <br> – Alternative regimen: 123}}
::* {{Regimen|Enterococcus| – Preferred regimen: 123 <br> – Alternative regimen: 123}}
::* {{Regimen|Fungus|– Preferred regimen: 123 <br> – Alternative regimen: 123}}
::* {{Regimen|Fungus| – Preferred regimen: 123 <br> – Alternative regimen: 123}}
::* Gonococcal
::* Gonococcal
::* Gram-negative bacilli
::* Gram-negative bacilli
::* {{Regimen|HACEK|– Preferred regimen: 123 <br> – Alternative regimen: 123}}
::* {{Regimen|HACEK| – Preferred regimen: 123 <br> – Alternative regimen: 123}}
::* Legionella
::* Legionella
::* {{Regimen|Staphylococcus_aureus|– Preferred regimen: 123 <br> – Alternative regimen: 123}}
::* {{Regimen|Staphylococcus_aureus| – Preferred regimen: 123 <br> – Alternative regimen: 123}}
::* {{Regimen|Streptococcus|– Preferred regimen: 123 <br> – Alternative regimen: 123}}
::* {{Regimen|Streptococcus| – Preferred regimen: 123 <br> – Alternative regimen: 123}}
::* Tropheryma whippleii
::* Tropheryma whippleii


Revision as of 06:10, 23 May 2015

  • Endocarditis[1]
  • Culture-negative endocarditis:
  • Native_valve_endocarditis
    – Preferred regimen: 123
    – Alternative regimen: 123
  • Prosthetic_valve_endocarditis
    – Preferred regimen: 123
    – Alternative regimen: 123
  • Culture-directed antimicrobial therapy:
  • Highly_Penicillin-Susceptible_Viridans_Group_Streptococci_and_Streptococcus_bovis
    – Preferred regimen: Penicillin G 12–18 million U/24 h IV either continuously or in 4 or 6 equally divided doses for 4 weeks OR Ceftriaxone 2g/24h IV/IM in 1 dose for 4 weeks (pediatric dose: penicillin 200,000 U/kg per 24 h IV in 4–6 equally divided doses; ceftriaxone 100 mg/kg per 24 h IV/IM in 1 dose)
    – Alternative regimen (1): Penicillin G 12–18 million U/24 h IV either continuously or in 6 equally divided doses for 2 weeks OR Ceftriaxone 2g/24h IV/IM in 1 dose for 2 weeks AND Gentamicin 3mg/kg per 24h IV/IM in 1 dose for 2 weeks (pediatric dose: penicillin 200 000 U/kg per 24 h IV in 4–6 equally divided doses; ceftriaxone 100 mg/kg per 24 h IV/IM in 1 dose; gentamicin 3 mg/kg per 24 h IV/IM in 1 dose or 3 equally divided doses)
    – Alternative regimen (2): Vancomycin 30 mg/kg per 24 h IV in 2 equally divided doses not to exceed 2 g/24 h for 4 weeks (pediatric dose: 40 mg/kg per 24 h IV in 2–3 equally divided doses)



  • Bartonella
    – Preferred regimen: 123
    – Alternative regimen: 123
  • Chlamydia
  • Coagulase-negative Staphylococcus
  • Coxiella_burnetii
    – Preferred regimen: 123
    – Alternative regimen: 123
  • Enterococcus
    – Preferred regimen: 123
    – Alternative regimen: 123
  • Fungus
    – Preferred regimen: 123
    – Alternative regimen: 123
  • Gonococcal
  • Gram-negative bacilli
  • HACEK
    – Preferred regimen: 123
    – Alternative regimen: 123
  • Legionella
  • Staphylococcus_aureus
    – Preferred regimen: 123
    – Alternative regimen: 123
  • Streptococcus
    – Preferred regimen: 123
    – Alternative regimen: 123
  • Tropheryma whippleii
  • Prophylactic therapy
  • Dental prophylaxis
  • Lyme carditis
  • Mycotic aneurysm
  • Implantable electronic device infections
  • Pericarditis
  • Bacterial pericarditis
  • Histoplasmosis
  • Extrapulmonary tuberculosis
  • Rheumatic fever
  • Cavernous sinus thrombosis
  • Intravenous line infections
  • Intravenous line infections, non-tunneled
  • Intravenous line infections, tunneled
  • Septic pelvic vein thrombophlebitis
  • Suppurative phlebitis
  • Ventricular-assist device infections

References

  1. ↑ Baddour, Larry M.; Wilson, Walter R.; Bayer, Arnold S.; Fowler, Vance G.; Bolger, Ann F.; Levison, Matthew E.; Ferrieri, Patricia; Gerber, Michael A.; Tani, Lloyd Y.; Gewitz, Michael H.; Tong, David C.; Steckelberg, James M.; Baltimore, Robert S.; Shulman, Stanford T.; Burns, Jane C.; Falace, Donald A.; Newburger, Jane W.; Pallasch, Thomas J.; Takahashi, Masato; Taubert, Kathryn A.; Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease; Council on Cardiovascular Disease in the Young; Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia; American Heart Association; Infectious Diseases Society of America (2005-06-14). "Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): –394-434. doi:10.1161/CIRCULATIONAHA.105.165564. ISSN 1524-4539. PMID 15956145.
Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox_ID_Cardiovascular&oldid=1101378"